SILO — Silo Pharma Income Statement
0.000.00%
Last trade - 00:00- $3.36m
- -$3.72m
- $0.07m
- 16
- 26
- 32
- 13
Annual income statement for Silo Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.071 | 0.072 | 0.072 | 0.072 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0.066 | 0.066 | 0.066 | 0.066 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.4 | 2.8 | 3.7 | 3.93 | 4.78 |
| Operating Profit | -2.4 | -2.73 | -3.63 | -3.86 | -4.71 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.67 | 4.18 | -3.91 | -3.63 | -4.39 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.67 | 4.16 | -3.91 | -3.63 | -4.39 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -3.04 | 3.9 | -3.91 | -3.7 | -4.39 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.11 | 2.5 | -3.91 | -3.7 | -4.39 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.92 | 1.43 | -1.71 | -1.18 | -1.19 |